Introduction
Psoriasis is dependent on Th1-and Th17-polarized CD4 T cells that produce pro-inflammatory cytokines (such as TNF-␣ ) and thus prompt the development of acanthosis and papillomatosis [1] . Blocking TNF-␣ greatly improves clinical outcomes [2, 3] and results in fewer (and generally milder) side effects than observed for older drugs (e.g. cyclosporin A or methotrexate). Common side effects are temporary headaches, nasopharyngitis, upper respiratory tract infections, injection site reactions, eczema and (more rarely) vasculitis [4] . Here, we report on 3 patients with psoriasis (variously with and without joint involvement) who developed isolated eosinophilia during TNF blockade.
Patient 1
A 46-year-old Caucasian male with a 30-year history of severe psoriasis and psoriatic arthritis was treated with a combination of adalimumab, anthralin and topical steroids. Prior to treatment, slight eosinophilia had been noted (730/ l of blood, relative to an upper normal limit of 700/ l). The serum tryptase level was normal ( ! 11.7 U/l). The patient had a history of seasonal allergic rhinitis but no other signs of atopy. Total IgE was ! 100 kU/l. Prior to initiation of adalimumab treatment, the patient had a Psoriasis Area and Severity Index (PASI) score of 11.3, which fell to 0.1 after 4.5 months of treatment. After 3.25 months of therapy, he developed eosinophilia (1,550/ l; fig. 1 a) . Eosinophilic cationic protein (ECP) was also elevated (38.20 g/l; normal range 1.8-13.3 g/l). A parasite screen was negative, and total IgE levels remained normal. No signs of a haematological disorder were found. The patient also reported transient urticarial skin changes that developed after the onset of adalimumab treatment but had resolved before clinical examination. After discontinuation of adalimu- tion and reporting of potential drug-related side effects is an important task for clinicians. However, deviations from normal laboratory values must be interpreted in a clinical context, and not all changes are necessarily of clinical relevance. Here, we report 3 cases of eosinophilia that were temporally associated with the administration of TNF antagonists. In 1 of 3 patients, eosinophilia resolved spontaneously during adalimumab treatment. Two patients developed de novo eosinophilia, and 1 patient's preexisting eosinophilia worsened. Some cases of eosinophilic pathology associated with TNF-␣ inhibitors have been observed before. Some cases of eosinophilic pathology associated with TNF-␣ inhibitors have been observed before. Etanercept-induced eosinophilic, cellulitis-like reactions and the development of Wells syndrome during adalimumab administration have been described [6, 7] . Comparable to our observation, Boura et al. [6] showed that the eosinophil pathology was associated with adalimumab. In addition, a patient with no history of atopy developed asthma during adalimumab therapy [8] . Vester et al. [9] reported a woman suffering from acrodermatitis continua of Hallopeau who had been treated with adalimumab and developed a transient blood eosinophilia. Moreover Cancelliere et al. [10] could show a connection between infliximab and etanercept administration and eosinophilia in a female patient treated for rheumatoid arthritis. The patient also developed clinical symptoms in terms of a subacute prurigo [10] .
Eosinophilia is stated as a less common side effect ( ! 1%) in the product monograph of adalimumab (Humira ) without providing further information on the severity or association with other clinical or serological findings [11] . In the eHealthMe database, eosinophilia has been observed during adalimumab treatment in 0.07% of reported side effects [12] . The majority of patients were in the 3rd or 5th decade, most of them were female and in about 80% the development of eosinophilia occurred within the first 2 years of treatment [12] . Psoriasis was not in the top underlying conditions of these patients, and there was no information about the severity of eosinophilia [12] .
We could not identify any other apparent explanation for the 3 patients' elevated eosinophil counts. There were no relevant parasitological infections or haematological disorders. Two patients (No. 1 and 3) had an atopic predisposition (albeit mild) that alone would have been unlikely to cause eosinophilia. Patient 1 developed severe eosinophilia after the introduction of adalimumab; During a treatment-free interval, the eosinophilia disappeared and then recurred after the re-introduction of etanercept. After a switch to adalimumab, the eosinophil count rose even higher initially and then spontaneously normalized. The mechanism of TNF inhibition leading to eosinophilia remains unclear. The generation of IgE-class-switched antibodies might lead to IgE-mediated drug hypersensitivity and subsequent eosinophilia [13, 14] . Furthermore, TNF antagonism might induce an immune deviation from the Th1 cytokine pattern of psoriasis to the Th2 phenotype [15] , which can lead to eosinophilia and elevated IgE levels [16] . Quaglino et al. [15] could show that patients suffering from psoriasis present an upregulation of Th1 and Th17 in the peripheral blood and a downregulation of regulatory T cell subsets at baseline. Patients responding to etanercept administration showed a significant reversal of the Th1/Th17 activation indicated by a downmodulation in the mRNA expression of the hallmark target genes and cytokines Stat-3/IL-23p19 and Stat-4/IL-12p35, and a concomitant upregulation of Th2 and regulatory T cell subsets as shown by GATA-3, Foxp3/IL-2 and circulating CD4+CD25+ bright FoxP3+ T cell subsets in all responsive patients [15] . This data showed the potential involvement of CD4+ T cell modulation in the mechanisms of response induction triggered by etanercept and possibly other TNF inhibitors. CD4+ T cell modulation can be effective in reversing the psoriatic phenotype, as Ghoreschi et al. [17] showed with IL-4 therapy in psoriatic patients that induced a marked clinical improvement by upregulation of IL-4-producing CD4+ T cells.
The Th1-Th2 balance shift might be the reason that during TNF antagonism eosinophilia and PASI showed a reciprocal relationship as seen in figure 1 a-c. The more effective and sustained the inhibition was, the stronger the eosinophilia. Thus, in some patients a pronounced TNF-␣ blockade may amplify an immune deviation to the Th2 phenotype [18] . Although we did not assay serum levels of IL-5 in the isolated cases described here, in the future we shall screen for any potential elevation of this cytokine [19] . TNF-␣ inhibitors might also be able to influence eosinophil apoptosis. Mature eosinophils have a lifespan of only 3-5 days and are then eliminated by apoptosis [20, 21] . The observation that adalimumab induced more pronounced effects than etanercept might reflect adalimumab's higher potential to reduce the PASI and therefore a stronger shift to Th2. Furthermore, different structural properties of both drugs may also play a role. Infliximab for example as a monoclonal antibody (but not etanercept) has been shown to induce apoptosis in lamina propria T lymphocytes in Crohn's disease [22] . Thus, the group of TNF-␣ antagonists is heterogeneous, and our findings might express this circumstance.
In general, TNF-␣ antagonists have been found to have differential effects on haematopoiesis. A psoriasis patient treated with infliximab developed severe neutrophilia [23] . In a study on chronic anaemia of patients with inflammatory bowel disease, 18 of 27 patients undergoing treatment with infliximab were anaemic; most of them had anaemia of chronic disease. Infliximab reduced disease activity and improved anaemia in 12 patients. This was mediated by an increased production of erythropoietin for the [24] . Global analysis of haemoglobin levels of 5 phase III trials for Crohn's disease (CHARM trial), rheumatoid arthritis (ATTRACT, ASPIRE and START trials) and ankylosing spondylitis revealed significant improvement of anaemia by infliximab and adalimumab [25] [26] [27] . Etanercept has even been used as a successful salvage treatment in severe aplastic anaemia [28] . On the other hand, blocking TNF-␣ can also have myelosuppressive effects. Infliximab has been used on a series of myelodysplastic patients with partial success [29] . Etanercept led to aplastic anaemia complicated by sepsis in a patient with rheumatoid arthritis [30] .
Infliximab produced severe neutropenia in a patient with rheumatoid arthritis, and rechallenge with infliximab as well as etanercept led to the same effect, arguing for a class effect in the respective patient [31] . Another report concerned infliximab-induced thrombocytopenia and neutropenia [32] . Adalimumab led to neutropenia in 2 cases [33, 34] , in 1 instance associated with expansion of the T-large granular lymphocyte compartment [34] .
Taken together, eosinophilia is a rare side effect of anti-TNF-␣ treatment. These case reports underline the importance of the early identification and reporting of potentially drug-induced adverse events. Side effects such as isolated eosinophilia are not clinically detectable but can potentially lead to severe organ damage caused by the release of toxic granule proteins (such as eosinophil-derived neurotoxin, ECP, eosinophil peroxidase and eosinophil major basic protein) [35] . This should be taken into account when persistent eosinophilia is identified during TNF-␣ inhibition.
